Cytokinetics Announces Non-Clinical Data From Multiple Programs to Be
Presented at the Biophysical Society 54th Annual Meeting
Presented at the Biophysical Society 54th Annual Meeting
Poster Presentations at Biophysical Society 54th Annual Meeting
The following abstracts are scheduled to be presented at the Biophysical Society 54th Annual Meeting:
Abstract #778-Pos: "The Small Molecule Skeletal Sarcomere Activator, CK-2017357, is a Calcium Sensitizer that Binds Selectively to the Fast Skeletal Troponin Complex." The poster presentation is scheduled on Sunday, February 21, 2010 during the Muscle Regulation I Poster Session in Hall D of the Moscone Center. The presenter, Raja Kawas, Cytokinetics, Inc., South San Francisco, CA will be present from 1:45 PM - 2:45 PM at poster board #B659.
Abstract #860-Pos: "The Molecular Mechanism of the Multi Tasking Kinesin-8 Motor." The poster presentation is scheduled on Sunday, February 21, 2010 during the Microtubule Motors-Kinesin-related Proteins Poster Session in Hall D of the Moscone Center. The presenter, Carolyn Moores, Ph.D., Birkbeck College, London, United Kingdom will be present from 1:45 PM - 2:45 PM at poster board #B741.
Abstract #1831-Pos: "The Small Molecule Smooth Muscle Myosin Inhibitor, CK-2018571, Selectively Inhibits ATP Hydrolysis and Relaxes Smooth Muscle in vitro." The poster presentation is scheduled on Monday, February 22, 2010 during the Muscle Regulation II Poster Session in Hall D of the Moscone Center. The presenter, Sheila Clancy, Cytokinetics, Inc., South San Francisco, CA will be present from 1:45 PM - 2:45 PM at poster board #B629.
Abstract #2803-Pos: "The Fast Skeletal Troponin Activator, CK-1909178 Reduces Muscle Fatigue in a Model of Peripheral Artery Disease in situ." The poster presentation is scheduled on Tuesday, February 23, 2010 during the Muscle: Fiber & Molecular Mechanics & Structure III Poster Session in Hall D of the Moscone Center. The presenter, Aaron Hinken, Ph.D., Cytokinetics, Inc., South San Francisco, CA will be present from 1:45 PM - 2:45 PM at poster board #B532.
Prior research from Cytokinetics' oncology program is also scheduled to be presented as part of a presentation during the Motility Subgroup Evening Talk on Saturday, February 20, 2010 at 8:00 PM, given by Steven S. Rosenfeld, M.D., Ph.D., Columbia University, New York, NY.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Contacts: Cytokinetics, Incorporated Christopher S. Keenan (Investors and Media) Director, Investor Relations (650) 624-3000
SOURCE: Cytokinetics, Inc.